A recent study has revealed that individuals using GLP-1 medications for obesity tend to reduce their physical activity levels once they initiate treatment. This research, which is set to be presented at the Endocrine Society’s annual meeting in Chicago, highlights a significant decrease in daily step counts among participants following the commencement of medication.
:max_bytes(150000):strip_icc():format(jpeg)/running-1-061526-d513d08c1257424882ee6369787eee22.jpg)
The study involved 753 participants whose daily activity levels were monitored before and after they began taking GLP-1 medications, which have gained popularity as an effective solution for weight management. Prior to starting the medication, the participants logged an average of 5,047 steps per day. After beginning the treatment, this figure dropped to approximately 4,487 steps. In terms of moderate-to-vigorous physical activity, the duration decreased from around 28 minutes to 22 minutes daily.
Notably, the largest declines in physical activity were observed among men and individuals suffering from joint or muscle pain. This raises concerns about the overall health implications of GLP-1 treatments, which are designed to suppress appetite and have enabled millions in the United States to achieve weight loss. Current estimates suggest that roughly one in eight Americans have tried a GLP-1 medication at some point, a trend that is likely to continue as these drugs are increasingly available in pill form instead of just as injectables.
Dr. Sajana Maharjan, the lead author of the study from HSHS St. John’s Hospital in Springfield, Illinois, emphasised the counterintuitive nature of the findings. “While many assume that weight loss leads naturally to increased physical activity, our study suggests otherwise. The findings in our study reinforce that exercise cannot be optional for people taking these medications,” she stated.
The decline in physical activity was not fully attributed to specific reasons, but it is worth noting that various side effects associated with GLP-1 medications—such as nausea, vomiting, and diarrhoea—could contribute to a decrease in both ability and motivation to engage in physical activity.
As individuals using GLP-1 medications navigate their weight-loss journey, experts underscore the necessity of maintaining an active lifestyle in tandem with pharmacological interventions. Dr. Maharjan stressed that “people need targeted interventions that encourage physical activity alongside medication for obesity.”
In addition to potential health risks posed by decreased physical movement, the implications for long-term physical and mental well-being are concerning. Regular exercise has many benefits, including improved cardiovascular health, enhanced mood, and increased muscular strength, all of which are vital, especially for those who are managing obesity.
The findings from this study raise important questions about the holistic approach to obesity treatment. While medications like GLP-1 are effective at reducing weight, they should not replace the need for regular exercise and lifestyle changes.
As the popularity of GLP-1 medications continues to grow, further research and comprehensive treatment plans that include physical activity are essential. Adjustments to patient education on the importance of exercise may help mitigate the potential decline in physical activity observed with these treatments. As healthcare providers discuss weight-loss strategies with their patients, integrating exercise routines could prove vital in sustaining weight loss and promoting a healthier lifestyle.
Overall, this study serves as a reminder of the necessity for a multifaceted approach to obesity management. While pharmacological advancements are significant, the role of physical activity within treatment plans must not be overlooked.